Compare Abbott Laboratories (ABT) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Quantum Computing Inc — how do they compare? Abbott Laboratories trades at $95.8 (market cap $166.94B), while Quantum Computing Inc trades at $8.62 (market cap $1.96B). The key difference: Abbott Laboratories is far larger — about 85.2× Quantum Computing Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| ABT | QUBT | |
|---|---|---|
Market Cap | $166.94B | $1.96B |
Sector | Health | Technology |
52-Week High | $136.62 | $24.62 |
52-Week Low | $82.57 | $6.31 |
Enterprise Value | $193.69B | $977.49M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
QUBT trades at $9.37, up 3.54% today, but technical indicators signal a bearish trend with support at $9. The company shows minimal revenue of $682K in 2025 with a net loss of $18.67M, resulting in negative margins. Recent acquisitions and a potential $10M deal with Planck Dynamics highlight growth efforts, but cash burn remains high. Analyst consensus is bullish with a $24 price target, citing commercialization potential in quantum photonics.
The outlook hinges on QUBT's ability to scale revenue and manage cash burn amid intense quantum computing competition. While analyst optimism and policy tailwinds offer upside, high valuation multiples and persistent losses pose significant risks. Investors should weigh the long-term potential against near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
